Stay updated with breaking news from Chang Kwon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Laos Ministry of Labour and Social Welfare signed a Memorandum of Understanding (MOU) last week in Vientiane to enable the seasonal employment of Lao workers in South Korea.
Aptose Biosciences Inc. announced today that it has entered into an exclusive license agreement with Hanmi Pharmaceutical, a South Korean pharmaceutical company, to develop and commercialize HM43239, an oral, highly potent, clinical-stage myeloid kinome inhibitor designed to target a distinct constellation of kinases operative in myeloid malignancies, including SYK, FLT3, and others. HM43239 has demonstrated ...
Monday, 22 March 2021, 02:36 Preparations for Ukraine Reform Conference in Switzerland discussed at President's Office 26.02.2021 15:43 Ukrinform Deputy Head of the Office of the President of Ukraine Ihor Zhovkva and Head of the Agency of Diplomatic Advisers to the President of Switzerland Térence Billeter discussed in a phone call preparations for the Ukraine Reform Conference to be held in Switzerland in 2022. This was reported by the press service of the President's Office on February 25. The interlocutors discussed topical issues of bilateral relations and the implementation of agreemen...
© 1995-2021 Businessgroup LLC All materials, including photographs, contained on this site are protected by copyright law and may not be reproduced without the prior written permission of Businessgroup LLC at news@kyivpost.com. All Interfax-Ukraine news agency stories cannot be reproduced or distributed in any form without written permission of Interfax-Ukraine. Translate » Dear reader, This is a friendly reminder that you should switch off your ad-blocker while visiting the Kyiv Post. We respect and understand your choice to avoid advertising, but most ad-blockers also prevent pages ...
LAPSTriple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion Efpeglenatide met the primary endpoint for global Phase 3 Striving for developing rare diseases such as a once-a-month drug for short-bowel syndrome SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. ...